SUNANDANA CHANDRA M.D. NPI 1265696348

NPI Details

Sunandana Chandra, M.D. is a medical oncology internal medicine in Chicago, IL with 18 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Sunandana Chandra, M.D. NPI is 1265696348. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: MICHIGAN STATE UNIVERSITY COLLEGE OF HUMAN MEDICINE
Graduation Year:2008

The provider's business location address is:

645 N. MICHIGAN AVENUE
SUITE 1006
CHICAGO, IL
ZIP 60611
Phone: (517) 896-3576

The NPI 1265696348 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, octreotide, depot form for intramuscular injection, 1 mg (HCPCS:J2353)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Unclassified drugs (HCPCS:J3490)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Hospital discharge day management, 30 minutes or less (HCPCS:99238)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)

The enumeration date for this NPI number is 7/17/2008 and was last updated on 5/6/2014.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: